Drugs / SAR341402
SAR341402
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03436498 | May → Oct 2018 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT03916601 | Dec 2017 → Mar 2018 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT03202875 | Nov → Dec 2012 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03874715 | Mar 2019 → Jul 2020 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03211858 | Aug 2017 → Jul 2018 | diabetes mellitus | Sanofi | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR341402 | “SAR341402 100 units per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection” NCT03211858 ↗ |
| Known as | insulin aspart | “Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by...” PMID 33432547 ↗ Jan 20212“Background: The objective of this study was to demonstrate the pharmacokinetic and pharmacodynamic similarity among SAR341402 insulin aspart biosimilar/follow-on product” PMID 31825248 ↗ Dec 2019 “SAR341402 (insulin aspart) Mix 70/30” PMID 33236518 ↗ Dec 2020 |
| Known as | SAR-Asp | “The biosimilar SAR341402 insulin aspart (SAR-Asp) was compared to its originator NovoLog®/NovoRapid® insulin aspart (NN-Asp)” PMID 33432547 ↗ Jan 20212“insulin aspart biosimilar/follow-on product SAR341402 (100 U/mL solution; SAR-Asp)” PMID 31833801 ↗ Jan 2020 “SAR341402 insulin aspart solution (SAR-Asp)” PMID 33236518 ↗ Dec 2020 |
| Known as | SARAsp -Mix | “SAR341402 Mix 70/30 (SARAsp -Mix)” PMID 33236518 ↗ Dec 2020 |
| Modality | Protein / enzyme biologic | “SAR341402 insulin aspart biosimilar/follow-on product” PMID 31825248 ↗ Dec 2019 |
| Route | Subcutaneous | “Route of administration: subcutaneous” NCT03202875 ↗ |